Biocon’s subsidiary -- Biocon Biologics (BBL) and its subsidiaries have executed a debt facility agreement which is classified as a Sustainability-linked Loan (SLL) amounting to $1.2 billion on November 20, 2022, the proceeds of which shall be used for funding the acquisition of Viatris Inc.’s biosimilars business and acquisition related expenses.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.